biotime inc (BTX) Key Developments
Aditya Mohanty Joins BioTime, Inc. as New Chief Operating Officer
Dec 29 14
On December 29, 2014, Aditya Mohanty joined BioTime, Inc. as its new Chief Operating Officer. Mr. Mohanty comes to the company from Shire plc, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012 to 2013, as Global Franchise Head MPS from 2010 to 2012, and as Vice President of Operations/Product General Manager from 2005 to 2012. Mr. Mohanty was VP of Manufacturing and Operations at Transkaryotic Therapies, Inc. from 2002 to 2005 when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions at Baxter Healthcare Corporation, Bioscience
Division from 1990 to 2002.
BioTime, Inc. Appoints Angus C. Russell to Board of Directors
Dec 15 14
BioTime, Inc. announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors. He currently serves on the boards of directors of Mallinckrodt plc and Revance Therapeutics, Inc.
BioTime, Inc. - Analyst/Investor Day
Dec 12 14
To discuss an overview of company’s growth opportunities and operational strategy
BioTime, Inc. Presents at LD Micro Conference, Dec-04-2014 04:00 PM
Dec 1 14
BioTime, Inc. Presents at LD Micro Conference, Dec-04-2014 04:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Michael D. West, Chief Executive Officer, President and Director.
BioTime, Inc. Appoints OUM & Co. LLP as Independent Registered Public Accountant
Nov 10 14
BioTime, Inc. announced that its AGM of shareholders held on November 4, 2014 ratified the selection of OUM & Co. LLP as independent registered public accountants to audit financial statements for the current fiscal year.